The German biotech industry has shown tremendous growth in 2017. According to figures of BIOCOM, turnover, employees or number of start-ups – many key figures for 2017 exceeded those of the record year 2016.
/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png00Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2018-04-18 07:48:492018-04-18 07:48:49Servier to bag Shire’s cancer business
Shortly before the Global Bioeconomy Summit (19.-20.4.2018) in Berlin will begin, Germany’s new Research Minister Anja Karliczek announced three major initiatives to strengthen the biologisation of the industry and the foundation of innovative biotechs.
https://european-biotechnology.com/wp-content/uploads/2024/04/anja_karliczek_2017_kampa_02-1024x683.jpg6831024Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2018-04-17 09:20:482018-04-17 09:20:48Germany to boost the bioeconomy
https://european-biotechnology.com/wp-content/uploads/2024/04/Pierre_Guerin_site.jpg450800Maren Kühr/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngMaren Kühr2018-04-16 00:00:002018-04-16 00:00:00New Pierre Guerin site in Hildesheim, Germany
https://european-biotechnology.com/wp-content/uploads/2024/04/Alexandra_Pearce.jpg321321h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2018-04-13 17:01:002018-04-13 17:01:00Abivax appoints Alexandra Pearce as VP of Regulatory Affairs
British drug major GlaxoSmithKline (GSK) has passed its orphan autologous cell and gene therapy pipeline including its EU-approved ADA-SCID treatment Strimvelis to British/US Orchard Therapeutics. GSK acquired a 19,9% equity stake in Orchard and a board membership.
A public offer from orphan drug major Alexion Pharmaceuticals Inc. has been accepted by Wilson Therapeutics‘ Board of Directors. Alexion’s SEK232/share bid would total in an acqusition price of SEK6.564bn or €638.8m.
https://european-biotechnology.com/wp-content/uploads/2024/04/Bildschirmfoto_2018-04-11_um_09.44.48.png268721Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2018-04-11 08:44:062018-04-11 08:44:06Alexion in €639m bid for Wilson Therapeutics AB
The Eppendorf DASbox mini bioreactor system with its small working volume, compact design, as well as advanced control, and information management options is ideal for research and early development processes.
https://european-biotechnology.com/wp-content/uploads/2024/04/DASbox.jpg9001600Maren Kühr/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngMaren Kühr2018-04-10 11:55:072024-04-02 15:51:43DASbox® Mini Bioreactor System: Most Compact System for Early Stage Processes
Swiss drug major Novartis has secured a potential stake in the multibillion dollar market of treatments for the orphan genetic muscle disease spinal muscular atrophy (SMA). The company acquired AveXis Inc, whose SMA gene therapy AVXS-101 is in Phase III testing.
German biotech sector growing
Latest NewsThe German biotech industry has shown tremendous growth in 2017. According to figures of BIOCOM, turnover, employees or number of start-ups – many key figures for 2017 exceeded those of the record year 2016.
Servier to bag Shire’s cancer business
Latest NewsFrench Servier boosts its cancer drug portfolio acquiring Shire plc’s oncology pipeline, which earned about US$260m last year, for US$2.4bn in cash.
Germany to boost the bioeconomy
Latest NewsShortly before the Global Bioeconomy Summit (19.-20.4.2018) in Berlin will begin, Germany’s new Research Minister Anja Karliczek announced three major initiatives to strengthen the biologisation of the industry and the foundation of innovative biotechs.
Canopy acquires Czech Annabis Medical sro
Latest NewsNew Pierre Guerin site in Hildesheim, Germany
Latest NewsMid last year, the company Pierre Guerin has opened a new location in Germany, Hildesheim.
Abivax appoints Alexandra Pearce as VP of Regulatory Affairs
AppointmentsDr. Pearce Joins as ABIVAX Works with FDA and EMA on Next Stage Developments of its Clinical Product Candidates
GSK pass orphan gene therapy assets to Orchard Therapeutics
Latest NewsBritish drug major GlaxoSmithKline (GSK) has passed its orphan autologous cell and gene therapy pipeline including its EU-approved ADA-SCID treatment Strimvelis to British/US Orchard Therapeutics. GSK acquired a 19,9% equity stake in Orchard and a board membership.
Alexion in €639m bid for Wilson Therapeutics AB
Latest NewsA public offer from orphan drug major Alexion Pharmaceuticals Inc. has been accepted by Wilson Therapeutics‘ Board of Directors. Alexion’s SEK232/share bid would total in an acqusition price of SEK6.564bn or €638.8m.
DASbox® Mini Bioreactor System: Most Compact System for Early Stage Processes
ProductsThe Eppendorf DASbox mini bioreactor system with its small working volume, compact design, as well as advanced control, and information management options is ideal for research and early development processes.
Novartis enters SMA race acquiring AveXis for US$8.7bn
Latest NewsSwiss drug major Novartis has secured a potential stake in the multibillion dollar market of treatments for the orphan genetic muscle disease spinal muscular atrophy (SMA). The company acquired AveXis Inc, whose SMA gene therapy AVXS-101 is in Phase III testing.